Relationship Between Risk of Atherosclerotic Cardiovascular Disease, Inflammation, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis

Brittany Weber, Dana Weisenfeld, Thany Seyok, Sicong Huang, Elena Massarotti, Leanne Barrett, Courtney Bibbo, Daniel H Solomon, Jorge Plutzky, Marcy Bolster, Marcelo Di Carli, Katherine P Liao, Brittany Weber, Dana Weisenfeld, Thany Seyok, Sicong Huang, Elena Massarotti, Leanne Barrett, Courtney Bibbo, Daniel H Solomon, Jorge Plutzky, Marcy Bolster, Marcelo Di Carli, Katherine P Liao

No abstract available

Keywords: coronary microvascular dysfunction; inflammation; rheumatoid arthritis.

Figures

Figure 1. Relationship between baseline ASCVD estimated…
Figure 1. Relationship between baseline ASCVD estimated cardiovascular risk and CFR.
CMD defined as CFR

References

    1. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al.; CANTOS Trial Group . Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131. doi: 10.1056/NEJMoa1707914
    1. England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036. doi: 10.1136/bmj.k1036
    1. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, Blankstein R, Dorbala S, Sitek A, Pencina MJ, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011;124:2215–2224. doi: 10.1161/CIRCULATIONAHA.111.050427
    1. Liao KP, Huang J, He Z, Cremone G, Lam E, Hainer JM, Morgan V, Bibbo C, Di Carli M. Coronary microvascular dysfunction in rheumatoid arthritis compared to diabetes mellitus and association with all‐cause mortality. Arthritis Care Res (Hoboken). 2021;73:159–165. doi: 10.1002/acr.24108
    1. Weber BN, Stevens E, Perez‐Chada LM, Brown JM, Divakaran S, Bay C, Bibbo C, Hainer J, Dorbala S, Blankstein R, et al. Impaired coronary vasodilator reserve and adverse prognosis in patients with systemic inflammatory disorders. JACC Cardiovasc Imaging. 2021;14:2212–2220. doi: 10.1016/j.jcmg.2020.12.031
    1. Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, et al. IL‐6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double‐blind, randomised, placebo‐controlled, phase 2 trial. Lancet. 2021;397:2060–2069. doi: 10.1016/S0140-6736(21)00520-1
    1. Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, Katsimbri P, Pavlidis G, Parissis J, Kremastinos D, Anastasiou‐Nana M, et al. Increased benefit of interleukin‐1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circulation: Cardiovasc Imaging. 2014;7:619–628. doi: 10.1161/CIRCIMAGING.113.001193

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する